Myocardial infarction within the past 6 months
Patients must not have a myocardial infarction within 6 months prior to registration
History of myocardial infarction within 6 months.
Acute myocardial infarction </=6 months prior to enrollment
Myocardial infarction within 6 months prior to study entry,
Myocardial infarction within the last 6 months
Acute myocardial infarction ?6 months prior to Day 1
Myocardial infarction within the previous 6 months before planned first dose of study drug
Myocardial infarction within 6 months of study dose
Subjects with myocardial infarction (heart attack) within 1 year
No uncontrolled arrhythmia; no myocardial infarction in the last 6 months
Myocardial infarction within 6 months prior to initiation of screening
Other serious intercurrent chronic or acute illness, including myocardial infarction or cerebrovascular event within 6 months
Any history of myocardial infarction in the past 12 months
Myocardial infarction and/or new ST elevation
Myocardial infarction,
Myocardial infarction within 6 months prior to screening, or pericardial effusion,
Have a recent history of myocardial infarction (within the past 2 months)
History of myocardial infarction within the last 6 months.
Myocardial infarction in the previous 12 weeks (from the start of treatment)
History of myocardial infarction within 6 months of the randomization
Patients within 6 months of myocardial infarction (MI) and stroke will be excluded
Myocardial infarction (MI) within 6 months of Screening Visit.
Myocardial infarction within the 6 months prior to study drug administration
History of a recent myocardial infarction (within one year), a past myocardial infarction (more than one year ago) along with current coronary symptoms requiring medications
Has history of myocardial infarction within the past 6 months.
Myocardial infarction within 3 months of registration.
Myocardial infarction within 6 months of starting study drug
Myocardial infarction within 6 months
History of myocardial infarction within 6 months prior to registration
Patients with history of myocardial infarction within 6 months
No stroke, myocardial infarction, or major surgery within 3 months of starting on therapy
Myocardial infarction within 6 months of study entry
No evidence of a history of a stroke or myocardial infarction within the last 6 months prior to study enrollment
No uncontrolled arrhythmia; no myocardial infarction in the last 6 months
Active ischemic heart disease or history of myocardial infarction within six months.
Myocardial infarction within 6 months of study entry
Myocardial infarction less than 6 months before study enrollment
Myocardial infarction or cardiac surgery within 6 months prior to enrollment
myocardial infarction in the previous six months
Myocardial infarction (MI) within 3 months. • Presence of active, uncontrolled infection. • Known central nervous system illness (e.g., Alzheimer's disease).
Myocardial infarction
History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within 6 months
Subjects that have had a myocardial infarction within the last 6 months
Patients with a history of myocardial infarction that is < 3 months prior to registration
Patients with a history of myocardial infarction that is < 3 months prior to registration
Transmural myocardial infarction within the last 6 months
History of myocardial infarction within 6 months
Myocardial infarction < 6 months prior to screening
Patients with a history of myocardial infarction or stroke within the last 6 months
Documented myocardial infarction within six months of enrollment.
Myocardial infarction (MI) within 6 months prior to the first dose of study drug;
Myocardial infarction (MI) within past 6 months before randomization
History of myocardial infarction within 6 months of study entry.
Myocardial infarction within 6 months prior to study entry
Active ischemic heart disease or history of myocardial infarction within six months.
Patients with documented myocardial infarction within six months of protocol entry
Myocardial infarction (MI) within the last 3 months
Recent (within twelve months) myocardial infarction.
Evidence of a history of a stroke or myocardial infarction within the last 6 months prior to study enrollment
Patients with a history of myocardial infarction that is < 3 months prior to registration
Myocardial infarction within 3 months of study initiation
History of myocardial infarction within 6 months of enrollment.
Transmural myocardial infarction within 3 months prior to step 1 registration
History of myocardial infarction
Acute myocardial infarction =< 12 months prior to starting drug
Subjects with a history of myocardial infarction within the last 6 months of screening.
Patients with a history of myocardial infarction within the 6 months prior to screening
Myocardial infarction
Myocardial infarction
Patients who have had a myocardial infarction within 6 months (24 weeks) prior to registration are not eligible
Transmural myocardial infarction within the last 6 months
myocardial infarction within 6 months prior to randomization;
No myocardial infarction < 6 months
Myocardial infarction
History of myocardial infarction within 6 months.
Myocardial infarction
Transmural myocardial infarction within the last 6 months
Myocardial infarction within the last 3 months
Transmural myocardial infarction within the last 6 months prior to registration
Patients who have had a myocardial infarction, intracranial bleed, or stroke within the past 6 months are not eligible
Subjects with active cardiovascular disease not medically controlled or those who have had myocardial infarction in the past 6 months..
Myocardial infarction within 6 months before the Day 1 visit.
History of myocardial infarction within 6 months prior to screening
Myocardial infarction within 6 months before C1D1.
Documented myocardial infarction <6 months from study entry
Acute myocardial infarction
Myocardial infarction (MI) within 6 months prior to the first dose of brigatinib
Subjects with a history of myocardial infarction within the last 6 months.
Myocardial infarction
Myocardial infarction within 6 months of registration
Patients within three months of a myocardial infarction
Myocardial infarction in the previous 12 weeks (from the start of treatment)
Subjects with a history of myocardial infarction within the last 6 months of screening.
Myocardial infarction in the previous 12 weeks (from the start of treatment)
Patients with a history of myocardial infarction that is < 3 months prior to registration
History of a myocardial infarction within 6 months
Myocardial infarction within the past 6 months before the first dose of study drug
History of myocardial infarction within 12 months prior to day 1 or clinically significant coronary disease
History of myocardial infarction within 6 months of enrollment
Myocardial infarction within 12 months prior to starting study
Myocardial infarction within four months prior to enrollment
Myocardial infarction within 6 months of treatment
History of myocardial infarction within 6 months prior to day 1
Acute myocardial infarction ?6 months prior to study participation
Myocardial infarction within 3 months prior to starting treatment
Patients with a history of myocardial infarction that is < 3 months prior to registration
Myocardial infarction in the previous 12 weeks (from the start of treatment)
History of myocardial infarction within 6 months
Past history of myocardial infarction in the prior 12 months
Myocardial infarction ? 6 months prior to enrolment.
History of myocardial infarction within 6 months prior to the first dose of study-drug treatment in Cycle 1
Myocardial infarction <6 months from study entry
History of myocardial infarction within the last 6 months
Myocardial infarction within 6 months prior to screening;
Myocardial infarction (MI) within 6 months prior to first study drug administration
Acute myocardial infarction ? 3 months prior to starting study drug
Myocardial infarction (MI) within 6 months prior to first study drug administration
Myocardial infarction within 6 months of Screening visit;
History of myocardial infarction within 6 months of Cycle 1, Day 1
History of myocardial infarction within 6 months prior to screening
Subject has had an acute myocardial infarction (AMI)
Cardiomyopathy or a myocardial infarction within the past 8 months.
Myocardial infarction (MI) within the prior 3 months
History of myocardial infarction within 6 months prior to first dose of study drug
Any history of myocardial infarction in the past 12 months
A myocardial infarction within 6 months prior to study entry;
Patients with documented myocardial infarction within six months of protocol entry
Myocardial infarction 6 months prior to screening
Acute myocardial infarction within 6 months before starting study drug.
Transmural myocardial infarction within the last 6 months prior to registration
Active myocardial ischemia (acute ST elevation or non ST elevation myocardial infarction [MI])
Patients with a history of myocardial infarction or ischemic heart disease within the past six months
Myocardial Infarction (MI) within 3 months
History of myocardial infarction or ischemic heart disease within the past six months
Patients with a history of myocardial infarction or ischemic heart disease within the past six months
Recent myocardial infarction
No clinical history of acute myocardial infarction within six months of registration
myocardial infarction (within the last 3 months)
Myocardial infarction (MI) in the last 6 months
Myocardial infarction
Recent myocardial infarction
History of myocardial infarction within 6 months of the enrollment
Acute myocardial infarction within 28 days
Has history of myocardial infarction within the past 6 months
Myocardial infarction within 3 months prior to C1D1.
History of prior myocardial infarction or arrhythmia
Acute myocardial infarction within 6 months before starting study drug.
Myocardial infarction within the last 6 months
Myocardial infarction within the last 6 months
History of cerebrovascular disease
No history of arterial thrombotic events such as myocardial infarction (MI), unstable angina pectoris or any ischemic or hemorrhagic cerebrovascular accident (CVA) within past 6 months
12. Subjects with any other concurrent, uncontrolled illness, including known psychiatric or substance abuse disorders which may interfere with the ability of the subject to cooperate and participate in the trial. Other examples of such conditions would include unstable angina, myocardial infarction (MI) or cerebrovascular accident (CVA) within 6 months of study entry.
Subjects with other uncontrolled medical conditions, e.g. myocardial infarction, cerebrovascular accident, diabetes or hypertension.
History of cerebrovascular accident (CVA) within 6 months prior to randomization or that is not stable
History of cerebrovascular accident (CVA) within 6 months prior to randomization or that is not stable
Severe uncontrolled cardiac disease within 6 months of study entry, including but not limited to uncontrolled hypertension; unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA).
History of arterial thromboembolic event in past 6 months (including cerebrovascular accident [CVA], myocardial infarction [MI])
Myocardial infarction or cerebrovascular accident (CVA) within 6 months.
History of a venous thromboembolic event, cerebrovascular accident (CVA), hepatic impairment, or heart failure
History of cerebrovascular accident (CVA), myocardial infarction or unstable angina within the previous 6 months before starting therapy.
Prior cerebrovascular accident (CVA) with persistent neurological deficit
No cerebrovascular accident (CVA) within 6 months, no myocardial infarction (MI) within 6 months
History of myocardial infarction or cerebrovascular accident within 6 months of enrollment date
History of cerebrovascular disease
No cerebrovascular accident (CVA) within 6 months, no recent myocardial infarction (MI) within 6 months
Patients with clinically significant cardiovascular disease: History of CVA (cerebrovascular accident) within 6 months, myocardial infarction or unstable angina within 6 months, unstable angina pectoris
Patients with clinically significant cardiovascular disease: history of cerebrovascular accident (CVA) within 6 months, myocardial infarction or unstable angina within 6 months, or unstable angina pectoris
History of cerebral vascular accident (CVA), myocardial infarction or unstable angina within the previous six months before starting therapy
Severe cerebrovascular disease (multiple CVA or CVA within 6 months)
Known history of cerebrovascular accident, myocardial infarction, or intracranial hemorrhage within 2 months of enrollment.
History of cerebrovascular accident, myocardial infarction or unstable angina within the previous 6 months before starting therapy
Seizure or cerebrovascular accident (CVA) in the last year
Clinically significant cardiomyopathy or cardiac complications, including recent myocardial infarction or cerebrovascular accident within one year, and/or unstable or uncontrolled angina
Patients with a known history of myocardial infarction or cerebrovascular accident are not eligible
Patients with any unstable medical issue (including cardiac issues as above, active treatment for pulmonary embolism, cerebrovascular accident [CVA], renal or hepatic insufficiency, active infection/sepsis requiring IV antibiotics)
Patient must have no history of cerebrovascular accident (CVA) within 6 months of randomization
History of cerebrovascular accident within the past 6 months
Cerebral Vascular Accident (CVA) within 3 months prior to consent.
Severe cerebrovascular disease (multiple CVA or CVA within 6 months)
Patients with a history of myocardial infarction, unstable angina, or cerebrovascular accident < 6 months prior to registration
Prior cerebrovascular accident (CVA) with persistent neurological deficit
Myocardial infarction or cerebrovascular accident within 6 months prior to study registration
History of cerebrovascular accident (CVA), myocardial infarction or unstable angina within the previous 6 months before starting therapy
No CVA within 6 months, no MI within 6 months
History of documented myocardial infarction or cerebrovascular accident
Cerebrovascular accident within prior 6 months
Patients with clinically significant cardiovascular disease: history of cerebrovascular accident (CVA) within 6 months, myocardial infarction or unstable angina within 6 months, or unstable angina pectoris
History of cerebral vascular accident (CVA) within 6 months
Substantial central nervous system (CNS) disease including\r\n* History of CNS bleeding\r\n* Mass lesions in the brain\r\n* Uncontrolled seizure disorder\r\n* Recent history of cerebrovascular accident (CVA) (e.g. within the past 6 months)
History of a stroke or cerebrovascular accident (CVA) within 6 months
Subject has history of severe/unstable angina, myocardial infarction or cerebrovascular accident within 6 months prior to the planned first dose of study drug.
Subject has history of severe/unstable angina, myocardial infarction or cerebrovascular accident within 6 months prior to the planned first dose of study drug.
Subject has history of severe/unstable angina, myocardial infarction or cerebrovascular accident within 6 months prior to the first dose of study drug.
Severe cerebrovascular disease (multiple cerebrovascular accidents [CVAs] or CVA within 6 months)
History of cerebrovascular accident (CVA) within 6 months prior to registration or that is not stable.
Concomitant diseases/conditions: Unstable angina, myocardial infarction, valvular heart disease, encephalopathy, ischemic attacks, hemorrhagic or ischemic cerebrovascular accident (CVA) or ongoing pulmonary embolism within last year, arrhythmia, hepatopathy, uncontrolled infection, hemoptysis or oxygen requiring dyspnea, known HIV infection, bleeding risk, muscular problems, peripheral neuropathy, Symptomatic or progressive brain metastases or leptomeningeal disease.
History of myocardial infarction or cerebrovascular accident within 6 months of enrollment date.
Known history of cerebrovascular accident in the past 6 months.
History of cerebral vascular accident (CVA) within 3 months prior to registration
History of CVA within six months
Subject has history of severe/unstable angina, myocardial infarction, or cerebrovascular accident within 6 months prior to the first dose of study drug.
Severe cerebrovascular disease (multiple CVA or CVA within 6 months)
Cerebrovascular accident (CVA) or stroke within the past 6 months
Patients with history of acute myocardial infarction (MI) or cerebrovascular accident (CVA) within the last 12 months
Patients with evidence/history of cardiac disease including congestive heart failure, symptomatic arrhythmia not controlled by medication, unstable angina or cardiac disease, history of acute myocardial infarction (MI) or cerebrovascular accident (CVA) within the past six months
Patients with history of serious cardiac events defined as: \r\n* Patients with a history of New York Heart Association class 3 or 4 heart failure, or history of myocardial infarction, unstable angina or cerebrovascular accident (CVA) within 6 months of protocol registration \r\n* Patients who have history of PR prolongation (grade 2 or higher) or atrioventricular (AV) block
Severe cerebrovascular disease (multiple CVA or CVA within 6 months)
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); or unstable angina within 6 months prior to enrollment
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); or unstable angina within 6 months prior to enrollment
Had within 6 months prior to enrollment: myocardial infarction (MI), cerebrovascular accident (CVA), uncontrolled congestive heart failure (CHF), significant liver disease, unstable angina
Severe uncontrolled cardiac disease within 6 months of study entry, including but not limited to uncontrolled hypertension; unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA).
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment
